The in-vitro uptake of four anthracyclines into leukemic cells was investigated. The accumulation was found to be dependent on the extracellular anthracycline concentration in a linear fashion. The steady state intracellular drug level was reached very quickly and was found to be correlated to the extracellular pH-value in the range between 6.4 and 7.4. Intracellular anthracycline accumulation was restricted in a leukemic subline (F 4-6 R), which was found to be 86 times more resistant to doxorubicin compared with its wild tpye (F 4-6). The importance of the initial uptake phase of anthracyclines into leukemic cells raises the question whether long-term "cardioprotective" anthracycline application schedules will retain the same antileukemic effect as conventional bolus injection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2007-1025273 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dual-Targeted Drug Delivery to Myeloid Leukemia Cells via Complement- and Transferrin-Based Protein Corona.
Nano Lett
January 2025
State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center, China-Japan Union Hospital of Jilin University, Changchun 130033, P. R. China.
Although traditionally regarded as an impediment, the protein corona can facilitate the advancement of targeted drug delivery systems. This study presents an innovative approach for targeting acute myeloid leukemia (AML) using nanoparticles with agglutinated protein (NAPs). Agglutinated transferrin and C3b in NAPs selectively bind to CD71 and CD11b, receptors that are overexpressed on myeloid leukemic cells compared to nonmalignant cells.
View Article and Find Full Text PDFModelling post-chemotherapy stem cell dynamics in the bone marrow niche of AML patients.
Sci Rep
October 2024
Institute for Computational Biomedicine-Disease Modeling, RWTH Aachen University, Aachen, Germany.
Acute myeloid leukemia (AML) is a stem cell-driven malignancy of the blood forming (hematopoietic) system. Despite of high dose chemotherapy with toxic side effects, many patients eventually relapse. The "7+3 regimen", which consists of 7 days of cytarabine in combination with daunorubicin during the first 3 days, is a widely used therapy protocol.
View Article and Find Full Text PDFA novel approach for the treatment of AML, through GHRH antagonism: MIA-602.
Rev Endocr Metab Disord
October 2024
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
Article Synopsis
- Acute myeloid leukemia (AML) is a highly aggressive form of leukemia in adults, commonly treated with chemotherapy and stem cell transplantation, but drug resistance is a major challenge with limited options for patients whose disease doesn't respond to treatment.
- This review discusses a new approach using growth hormone-releasing hormone (GHRH) antagonists, which show promise in overcoming resistance and achieving better treatment outcomes based on pre-clinical studies.
- GHRH antagonists not only exhibit strong anti-cancer effects in AML cell lines but can also work alongside traditional treatments like anthracyclines to enhance their effectiveness, making them a potential game-changer in AML therapy.
Low-dose treatment with Epirubicin, a novel histone deacetylase 1 inhibitor, exerts anti-leukemic effects by inducing ferroptosis.
Eur J Pharmacol
December 2024
State Key Laboratory of Trauma and Chemical Poisoning, Medical Center of Hematology, Military Key Clinical Specialty, Chongqing Key Clinical Specialty, Chongqing Key Laboratory of Hematology and Microenvironment, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China. Electronic address:
Article Synopsis
- Leukemia is a type of cancer with poor treatment outcomes, and there is a need for new inhibitors of the protein HDAC1, which is highly expressed in leukemia.
- Researchers discovered potential HDAC1 inhibitors through virtual drug screening, and they tested the effectiveness of a candidate (Epirubicin - Epi) using several assays in lab settings and a mouse model.
- Results showed low doses of Epi can effectively inhibit leukemia cell growth and induce a type of cell death called ferroptosis, which may offer a safer and more effective treatment option compared to existing HDAC1 inhibitors.
Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia.
Leukemia
January 2025
Department of Pediatric Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, 215000, China.
Article Synopsis
- Acute myeloid leukemia (AML) is a serious blood cancer that needs new treatment options, and this study highlights phosphodiesterase 3A (PDE3A) as a potential drug target.
- Researchers found that PDE3A is overexpressed in AML cells compared to normal cells, and high levels of PDE3A are linked to worse outcomes for patients.
- The study revealed that the PDE3A inhibitor anagrelide (ANA) can effectively suppress the growth of AML cells with high PDE3A levels, especially when used in combination with the chemotherapy drug idarubicin (IDA), which leads to enhanced anti-cancer effects through a process called pyroptosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!